Human core 1 ␤3-galactosyltransferase (C1␤3Gal-T) generates the core 1 O-glycan Gal␤1-3GalNAc␣1-Ser͞Thr (T antigen), which is a precursor for many extended O-glycans in animal glycoproteins. We report here that C1␤3Gal-T activity requires expression of a molecular chaperone designated Cosmc (core 1 ␤3-Gal-T-specific molecular chaperone). 
T
he O-glycans in human glycoproteins and mucins are important in many aspects of cellular metabolism and cellular interactions, including those involved in leukocyte trafficking (1, 2) . The biosynthesis of mucin-type O-glycans in animal mucins and other glycoproteins is orchestrated by a family of Nacetylgalactosaminyltransferases that transfer GalNAc to specific Ser͞Thr residues to generate GalNAc␣1-Ser͞Thr, also known as the Tn antigen (3) . Subsequently, this precursor is the acceptor for core 1 ␤3-galactosyltransferase (C1␤3Gal-T or T-synthase) to generate the core 1 disaccharide O-glycan Gal␤1-3GalNAc␣1-Ser͞Thr (4, 5) , also known as the T antigen or Thomson-Friedenrich antigen. Unlike most glycosyltransferases, which occur in gene families, a single human gene on chromosome 7p14-p13 encodes the C1␤3Gal-T (4), although there is a pseudogene for C1␤3Gal-T on chromosome 5 (unpublished data). Other core structures for mucin-type O-glycans are known, but core 1 is the common core structure found on human erythrocytes and most lymphocytes, and it serves as a precursor for the branched core 2 O-glycan core Gal␤1-3(GlcNAc␤1-6)GalNAc␣1-Ser͞Thr found on human leukocytes and which are required to generate ligands for P-selectin in leukocyte adhesion (2, 6) . The factors regulating expression of core 1 O-glycans and T-synthase activity are of interest because Tn and sialyl Tn antigens are recognized as tumor-associated antigens for breast and colon carcinomas (7, 8) , and the inability to synthesize core 1 O-glycan is a potentially contributing factor to several autoimmune diseases, including IgA nephropathy (9) , Tn-syndrome (10) , and Henoch-Schönlein purpura (11) .
Intriguingly, the human T leukemic cell line Jurkat cells lack C1␤3Gal-T activity, lack core 1 O-glycans, and generate the Tn antigen (12, 13) . Thus, an alteration in the expression of the C1␤3Gal-T is predicted to cause global changes in O-glycan structures in multiple glycoproteins. In exploring the factors that regulate C1␤3Gal-T activity in Jurkat cells, we identified a protein that associates with C1␤3Gal-T and is required for its activity. We have designated this protein, which has the properties of a chaperone, Cosmc (core 1 ␤3-Gal-T-specific molecular chaperone). Here, we show that a mutation in Cosmc in Jurkat cells causes loss of C1␤3Gal-T activity and targeting of the inactive protein to the proteasome. Thus, mutations in Cosmc may contribute to expression of Tn antigen in tumor cells and human autoimmune diseases.
Materials and Methods RT-PCR, PCR, Cloning of the RT-PCR Product, and Sequencing.
Total RNA and genomic DNA from 5 ϫ 10 7 cells of Jurkat (clone E6-1, ATCC TIB 152), Molt-4, and K562 cells were isolated by using the total RNA isolation kit (The RNA Company, Austin, TX) and QIAgen DNA mini kit (Qiagen, Valencia, CA). For RT-PCR of Cosmc, the forward primer was 5Ј-CTCCATAGAG-GAGT TGT TGC-3Ј, and the reverse primer was 5Ј-TCACGCTTTTCTACCACTTC-3Ј. RT-PCR was performed in one step in 25 l of reaction containing 500 ng of total RNA, RT͞Tag mix, and primers (SuperScript One-Step RT-PCR kit, Invitrogen). The RT-PCR product was analyzed on a 1% Tris-acetate EDTA (TAE) agarose gel, and the expected 1,218-bp band was excised; the DNA was then extracted from the gel by using a QIAquick gel extraction kit (Qiagen). One-tenth of the product was cloned into PCR3.1(ϩ) (Invitrogen) by TA cloning and sequenced. To examine the sequence of Cosmc, PCR was performed by using genomic DNA as the template. Because human Cosmc contains a single exon, the same primer pair was used for both RT-PCR and PCR of Cosmc. The PCR product was analyzed on a 1% TAE agarose gel, and the expected 1,218-bp band was excised, purified, and directly sequenced. tagged human C1b3Gal-T was constructed by using PCR for introducing the HPC4 epitope into the cDNA. The forward primer was 5Ј-GCGGATCCATGGCCTCTAAATC-3Ј. The reverse primer containing sequence, encoding 12 aa of HPC4 epitope (EDQVDPRLIDGK) immediately following the Cterminal proline of human C1b3Gal-T, was 5Ј-GGAAGAT-CTACTTGCCGTCGATCAGCCTGGGGTCCACCTGGT-CCTCAGGATTTCCTAACTTCACTTTTG-3Ј. The expected 1,144 bp of PCR product was purified on 1% TAE agarose gel and digested by NcoI and BglII. The expected 1,128-bp DNA fragment was purified and cloned into NcoI (partially digested)͞ BamHI sites of pcDNA4 and its sequence was confirmed. For construction of an insect cell expression vector, the PCR product was digested with BamHI and BglII, and the 1,134-bp DNA fragment was purified and cloned into the BamHI site of pVL1393 (PharMingen). Thus, a baculovirus transfer vector encoding a C-terminal HPC4 epitope-tagged human C1b3Gal-T in pVL1393 was constructed.
Construction of an Expression Vector Encoding Human C-Terminal
His-6-Tagged Cosmc. A cDNA encoding Cosmc with a C-terminal His-6 tag was generated by introducing the His-6 tag into Comsc cDNA by using PCR and EST AA578739 (Genome Systems) as a template. The PCR product was subcloned into pcDNA3.1(ϩ) by using BamHI͞XbaI sites. Similarly, a baculovirus transfer vector encoding human C-terminal His-6-tagged Cosmc was constructed through subcloning of the Cosmc cDNA into pVL1393.
Construction of an Expression Vector Encoding Human Mutated Cosmc
(mCosmc). An expression vector encoding mCosmc was constructed by replacing the HindIII͞XbaI fragment of wild-type Cosmc (wtCosmc) in pCDNA3.1(ϩ) with a mutated fragment of mCosmc in PCR3.1 vector generated by TA cloning of the RT-PCR of mCosmc from Jurkat cells. A baculovirus transfer vector encoding human mCosmc was constructed by subcloning the mCosmc cDNA from pcDNA3.1(ϩ) into pVL1393.
Preparation of Baculovirus. Sf-9 insect cells were cultured in 5 ml of Sf-900II SFM with 10% FBS at 27°C and cotransfected with pVL1393 vector and baculovirus DNA by using the BaculoGold transfection kit (PharMingen). The media containing the baculovirus were harvested 4 days posttransfection. For large-scale preparation of baculovirus, Sf-9 cells in 25 ml of media were infected with 0.25 ml of baculovirus obtained above. The baculovirus (media) was collected 4 days postinfection and used for expression of human C1␤3Gal-T and Cosmc.
Preparation of Cell Extracts. Transfected or infected cells were resuspended in an appropriate volume of 25 mM Tris⅐HCl buffer (pH 7.5) containing 150 mM NaCl and proteinase inhibitor mixture (Roche Molecular Biochemicals) and homogenized by sonication on an ice-bath for 5 s four times. The postnuclear supernatants were obtained by centrifugation of homogenate at 700 ϫ g for 10 min, and the extracts were obtained by adding 1% Triton X-100 to the supernatant and solubilizing on ice for 30 min.
Expression of Human C1␤3Gal-T and Cosmc in 293T Cells. Human 293T cells were transiently transfected with expression vectors encoding a C-terminal HPC4 epitope-tagged human C1␤3Gal-T and͞or the expression vector encoding human C-terminal His-6-tagged Cosmc or mCosmc, by using FuGENE 6 (Roche Molecular Biochemicals). Cells were harvested 72 h posttransfection, and a cell extract was prepared. One portion was assayed for C1␤3Gal-T activity by using GalNAc␣1-O-phenyl (Sigma) as the acceptor (5), and the other portion was used for capture of Cosmc on Ni-NTA Superflow and capture of C1␤3Gal-T on HPC4 beads, prepared as described (4) , and Western blot. HPC4-tagged C1␤3Gal-T in 500 l of cell extract was captured with HPC4 UltraLink beads (100 l) as described (4).
Capture of Human Cosmc on Ni-NTA Superflow. The Ni-NTA Superflow beads (100 l, Qiagen) equilibrated with the Ni-NTA washing buffer containing 50 mM NaH 2 PO 4 , 300 mM NaCl, 20 mM imidazole, and 0.1% Triton X-100 (pH 7.8) were incubated with the cell extracts overnight at 4°C on a rotator. The beads were washed five times with 1 ml of the washing buffer. One portion of the beads was removed for C1␤3Gal-T enzyme assay. The bound material in the other portion was eluted with 100 l of eluting solution (50 mM NaH 2 PO 4 ͞300 mM NaCl͞250 mM imidazole͞0.1% Triton X-100).
Western Blot of Human HPC4 Epitope-Tagged C1␤3Gal-T. Ten to 20 microliters of cell extract, unbound material, and 25 l of Ni-NTA bound material were electrophoresed on an SDS͞ PAGE (4-20%) under reducing conditions and transferred to a nitrocellulose membrane (Bio-Rad). The samples were Westernblotted for the HPC4 epitope by using 10 g͞ml HPC4 mAb at room temperature for 1 h, as described (4).
Results
Identification of Cosmc. The human T-leukemic cell line Jurkat is deficient in C1␤3Gal-T activity and expresses truncated O-glycans bearing the Tn antigen (12, 13) . We first considered the possibilities that the lack of C1␤3Gal-T activity might be caused by either a mutation in the C1␤3Gal-T gene or transcriptional regulation of C1␤3Gal-T expression. We found, however, that the transcript level for the C1␤3Gal-T in Jurkat cells is much higher than that in the human lymphoblastoid cell line MOLT-4, which has relatively high levels of C1␤3Gal-T activity (data not shown), and that the cDNA sequence for the C1␤3Gal-T derived from Jurkat cells was normal. Thus, there is no mutation in the C1␤3Gal-T gene in Jurkat cells, and the cells have normal transcripts, yet lack C1␤3Gal-T enzyme activity. Human C1␤3Gal-T is an Ϸ42-kDa subunit, dimeric enzyme, which is unusual in lacking common posttranslational modifications, such as addition of N-glycans (4) . Surprisingly, we also found that expression of a recombinant, epitope-tagged form of the enzyme in Jurkat cells, as discussed below, did not result in any detectable recombinant protein. Together, these results demonstrated that some other factor(s) may posttranscriptionally regulate expression of the C1␤3Gal-T protein and enzyme activity.
A clue to this other factor(s) was obtained by examining protein sequence data obtained during the purification of the C1␤3Gal-T from rat liver. N-terminal sequences of a partially purified C1␤3Gal-T, which migrated as a monomer at Ϸ42-43 kDa and a dimer at Ϸ84-86 kDa, were obtained (5) . Two amino acid sequences of different proportions were observed for the Ϸ84-to 86-kDa material at each sequence cycle in the partly purified preparation. One sequence (ASKSWLNFL) was identified as corresponding to the now defined C1␤3Gal-T (4, 5), whereas the other sequence (MLSESSSFLKGVMLGSIF) was derived from an unknown protein(s). BLASTP search of the National Center for Biotechnology Information EST database by using this N-terminal peptide sequence identified a human EST, AA578739, which contains one ORF of 954 bp (Fig. 1A) . A BLAST search using this sequence identified a human P-1-derived artificial chromosome clone RP4-655L22 (GenBank accession no. AC011890). This clone, derived from chromosome Xq23, contained a full-length ORF in a single exon. The gene present in RP4-655L22 is predicted to encode a 318-aa protein with type 2 membrane topology, a short cytoplasmic N terminus, a single transmembrane domain, a large C-terminal domain (Ϸ36.4-kDa polypeptide size), and one N-glycosylation sequon at Asn-313. Interestingly, the mature form of Cosmc retains the N-terminal Met residue. A homolog of this gene was found in mice, as discussed below, but no homologs were found in Caenorhabditis elegans or Drosophila. We considered whether the protein encoded by this gene was a potential accessory protein of unknown function to the C1␤3Gal-T. Based on studies described below, this protein was designated Cosmc.
Mutation of Cosmc in Jurkat Cells. We sequenced the cDNA for Cosmc from Jurkat cells and identified a T deletion at nucleotide position 478. This deletion causes a frameshift and the introduction of a stop codon ( Fig. 1 B and C) , resulting in a predicted mCosmc protein lacking most of the C-terminal domain (Fig.  1D) . The Cosmc gene is encoded by a single exon, and we also sequenced the DNA after PCR. The DNA from Jurkat cells also encoded a single T deletion at the same position as seen in the cDNA. Jurkat cells were originally derived from a 14-year-old male (14) , and because Cosmc is X-linked, we would expect the cells to have only a single copy of the Cosmc gene.
Chaperone Function of Cosmc. The mutation in Cosmc in Jurkat cells and the lack of expression of C1␤3Gal-T by these cells led us to test the possible chaperone function of Cosmc. For this we exploited our observation that expression of the human C1␤3Gal-T in Hi-5 insect cells anomalously resulted in a recombinant form of the enzyme lacking activity. Insect cells have very low levels of endogenous C1␤3Gal-T activity (15) . For these studies, we prepared epitopetagged recombinant forms of C1␤3Gal-T and Cosmc. A C-terminal His-6 tag chimeric form of wtCosmc was generated (bound by Ni-NTA columns), and a C-terminal 12-aa HPC4 epitope-tagged chimeric form of C1␤3Gal-T was generated. The HPC4 epitope is recognized by the Ca 2ϩ -dependent mAb HPC4 (16, 17) . Coexpression of wtCosmc with the C1␤3Gal-T in Hi-5 cells resulted in a substantial recovery of total enzyme activity, whereas coexpression with mCosmc only slightly enhanced enzyme activity ( Fig. 2A ). These results demonstrate that expression of Cosmc is required for the activity of human C1␤3Gal-T. We also examined the potential role of Cosmc expression in human 293T cells, which have an endogenous, functional C1␤3Gal-T and Cosmc. Interestingly, activity of recombinant C1␤3Gal-T was enhanced by coexpression with Cosmc but not with mCosmc (Fig. 2D) . The higher level of activity observed when recombinant C1␤3Gal-T was coexpressed with Cosmc in 293T cells, compared with the activity observed when only recombinant C1␤3Gal-T was expressed (Fig. 2D) , raises the possibility that the endogenous levels of Cosmc may be ratelimiting, but this will need to be further explored.
Association of Cosmc and C1␤3Gal-T.
To directly examine whether Cosmc can associate with C1␤3Gal-T, we asked whether some C1␤3Gal-T activity could be bound by Ni-NTA when the HPC4-tagged C1␤3Gal-T was coexpressed with His-6-tagged wtCosmc. The results show that some of the active C1␤3Gal-T is cobound with wtCosmc on Ni-NTA, but not when coexpressed with mCosmc in either Hi-5 cells (Fig. 2B) or 293T cells (Fig.  2E) . We also found that active HPC4-tagged C1␤3Gal-T was recoverable from Hi-5 cells on HPC4 beads when the enzyme was coexpressed with wtCosmc, but much less activity (Ϸ2%) was detectable when coexpressed with mCosmc (Fig. 2C) . Whereas expression of the HPC4-tagged C1␤3Gal-T in 293T cells gave rise to active enzyme captured by the anti-HPC4 column, coexpression with the wtCosmc, but not mCosmc, enhanced this activity (Fig. 2F ). These results demonstrate that Cosmc associates with C1␤3Gal-T and that expression of active C1␤3Gal-T requires coexpression with wtCosmc.
To confirm that Cosmc and C1␤3Gal-T can associate, we performed Western blots on the HPC4-tagged C1␤3Gal-T expressed in Hi-5 cells and 293T cells with or without His-6-tagged wtCosmc or mCosmc. When HPC4-tagged C1␤3Gal-T was expressed in Hi-5 cells and 293T cells in the absence or presence of wtCosmc or mCosmc, a considerable amount of protein was generated ( Fig. 2 G and H) , but the enzyme lacked activity except when coexpressed with wtCosmc ( Fig. 2 A-C) . More importantly, HPC4-tagged C1␤3Gal-T was present with His-6-tagged wtCosmc when the latter was captured on Ni-NTA ( Fig.  2 G and H) . By contrast, coexpression with mCosmc did not result in coisolation of HPC4-tagged C1␤3Gal-T (Fig. 2 G and  H) . There was a slight amount of HPC4-tagged C1␤3Gal-T detected in the Ni-NTA bound material in the absence of His-6-tagged wtCosmc from 293T cells (Fig. 2H) . Remarkably, this could result from cobinding of HPC4-tagged C1␤3Gal-T to endogenous Cosmc, as the N-terminal domain of Cosmc contains the sequence HHHEHHH (Fig. 1 A) , which may have weak binding to Ni-NTA. This finding might explain why there was a low level of C1␤3Gal-T activity (Fig. 2E ) in the material bound by Ni-NTA in the absence of recombinant Cosmc expression.
Complementation of Jurkat Cells by wtCosmc. We next tested whether wtCosmc could complement the mutation of the gene observed in Jurkat cells. The C-terminal, HPC4-tagged fulllength C1␤3Gal-T was transiently expressed in Jurkat cells along with wtCosmc, and we measured the total C1␤3Gal-T activity in cell extracts and HPC4-bound C1␤3Gal-T from cell extracts. Expression of wtCosmc in Jurkat cells enhanced the activity of the endogenous C1␤3Gal-T (Fig. 3A) , whereas expression of the HPC4-tagged C1␤3Gal-T in the absence of wtCosmc only slightly enhanced the total cellular activity (Fig. 3A) . These results demonstrate that Cosmc can complement the defective mCosmc in Jurkat cells. Expression of full-length HPC4-tagged C1␤3Gal-T in the absence of coexpressed wtCosmc somewhat elevated the cellular amount of HPC4-tagged C1␤3Gal-T captured on HPC4 beads, but coexpression with wtCosmc considerably enhanced the cellular content of HPC4-tagged C1␤3Gal-T captured on HPC4 beads (Fig. 3B) . We then examined the activity of a stably expressed, soluble, N-terminally HPC4-tagged C1␤3Gal-T in Jurkat cells. No activity of the soluble HPC4-tagged C1␤3Gal-T was detectable in media when expressed in Jurkat cells in the absence of coexpressed wtCosmc (Fig. 3C ), whereas coexpression with wtCosmc caused the production of significant levels of C1␤3Gal-T activity captured on HPC4 beads (Fig. 3C) . We further tested whether expression of wtCosmc in Jurkat cells could restore expression of core 1 O-glycan. To this end, we transfected Jurkat cells with cDNA encoding wtCosmc and tested the cells for their binding and agglutination by PNA. PNA binds well to the T antigen but does not recognize the Tn antigen (18, 19) . To test for exposure of T antigen, cells were desialylated by treatment with neuraminidase, as PNA will not bind the sialylated T antigen. As shown in Fig. 3D , PNA was unable to agglutinate mock-transfected Jurkat cells, but it quantitatively agglutinated desialylated Jurkat cells stably expressing wtCosmc. In control experiments, this PNAinduced agglutination of desialylated Jurkat cells expressing wtCosmc was completely inhibited by lactose, demonstrating that the PNA-induced agglutination was carbohydratedependent (data not shown). These results demonstrate that the mutation of Cosmc in Jurkat cells can be complemented by wtCosmc causing elevation of endogenous C1␤3Gal-T activity, restoration of the biosynthesis of core 1 O-glycans, and generation of an active, soluble, secreted form of HPC4-tagged recombinant C1␤3Gal-T.
We noted that the recombinant HPC4 epitope-tagged C1␤3Gal-T protein does not accumulate in Jurkat cells in the absence of coexpressed wtCosmc (Fig. 3E) . Unfolded proteins in the endoplasmic reticulum (ER) are targeted for degradation by the proteasome (20) . To test whether the inactive C1␤3Gal-T in Jurkat cells is degraded in the ER, we treated Jurkat cells stably expressing the soluble HPC4 epitope-tagged C1␤3Gal-T with the proteasome inhibitor lactacystin (21). Treatment of these Jurkat cells with lactacystin causes a significant increase in accumulation of the tagged protein (Fig. 3E) , although the recombinant protein was still an inactive enzyme (data not shown). These results indicate that in the absence of Cosmc expression, the C1␤3Gal-T is inactive and targeted for proteasome degradation.
Discussion
We have shown that expression of the active form of C1␤3Gal-T (T-synthase) requires the coexpression of a unique molecular chaperone Cosmc. Cosmc contains a single exon encoding a predicted protein of Ϸ36.4 kDa. Cosmc is mutated in human Jurkat cells and generates a cDNA containing a T deletion resulting in a frameshift and predicted truncation of the mutated protein. Furthermore, our studies show that Cosmc can associate with C1␤3Gal-T and that wtCosmc can complement the defect in Jurkat cells and restore core 1 O-glycan biosynthesis. These results suggest a model of how Cosmc might function in the biosynthesis of the active form of C1␤3Gal-T (Fig. 4) . Cosmc may associate with folding intermediates of C1␤3Gal-T, but whether this is a large oligomeric complex containing both native and partially unfolded forms of C1␤3Gal-T (CUA), as opposed to complexes only of Cosmc and unfolded C1␤3Gal-T (CUUC), is not yet defined. However, the presence of some C1␤3Gal-T activity associated with Cosmc (Fig. 2) argues for the occurrence of some mixed complexes, such as CUA (Fig. 4) . It is possible that other proteins, e.g., other chaperones, may also be present in complexes with Cosmc and C1␤3Gal-T. Cosmc is not associated with the soluble active form of the recombinant C1␤3Gal-T (data not shown), so Cosmc is not a subunit of C1␤3Gal-T, which is consistent with our observation that highly purified rat liver C1␤3Gal-T was also devoid of Cosmc (5). Thus, Cosmc seems to be a required cofactor for the generation of an active form of C1␤3Gal-T, as complementation of the mutated Cosmc in Jurkat by wtCosmc restores C1␤3Gal-T activity, and only inactive protein can be generated in insect cells in the absence of Cosmc coexpression. Such a cofactor function is consistent with a chaperone-assisted folding function of Cosmc. C1␤3Gal-T occurs as a disulfide-bonded dimer, but monomeric forms of the enzyme may also be active (5) . It is also likely that Cosmc occurs in a dimeric form, based on preliminary observations. Thus, Cosmc might associate with the C1␤3Gal-T during its folding in the ER, although we have no direct evidence at present as to the subcellular localization of Cosmc. In this light it is especially interesting that recombinant HPC4 epitope-tagged C1␤3Gal-T protein does not accumulate in Jurkat cells unless coexpressed with wtCosmc. The recombinant HPC4 epitope-tagged C1␤3Gal-T protein can be rescued from degradation by the proteasome inhibitor lactacystin, indicating that Cosmc may function in facilitating C1␤3Gal-T folding͞stability and trafficking out of the ER. Of course, other chaperones or cochaperones may also be involved in the folding or stability of the human C1␤3Gal-T.
It is noteworthy that Jurkat cells have many other glycosyltransferases whose activities seem normal because the only primary glycosylation phenotype identified to date in these cells is the deficiency of the C1␤3Gal-T activity (13) . The results strongly suggest that Cosmc is a specific chaperone for C1␤3Gal-T, although future studies are required to determine whether Cosmc associates with proteins other than C1␤3Gal-T. Northern blot analysis of Cosmc expression in human tissues reveals that Cosmc expression mirrors that observed for C1␤3Gal-T (ref. 4 and data not shown), consistent with a potential specific role of Cosmc in regulating C1␤3Gal-T expression. Several such protein-specific chaperones have been identified for other ligands, including HSP47, a collagen-specific molecular chaperone (22) , calmegin, which is specific for alpha͞ beta fertilin (23) , the copper chaperone for superoxide dismutase (CCS-1) (24), and many others (25) , although Cosmc is a molecular chaperone known to be required for a specific glycosyltransferase. Some molecular chaperones, such as HSP40, HSP60, and HSP90, interact with proteins to stabilize intrinsically unstable folding intermediates (26, 27 ). The precise mechanism of function of Cosmc awaits further study. It is interesting that the mouse gene (GenBank accession no. NP_067525), which we believe encodes the ortholog of human Cosmc, was one of several genes studied by screening a cDNA library for genes causing the growth suppression of Escherichia coli (28) . The authors of that study found that the protein encoded by NP_067525 had ATP binding activity, consistent with a possible ATP-dependent chaperone function for the human Cosmc. The protein encoded by mouse Cosmc is predicted to contain 316 aa, two residues shorter than the human ortholog, with 91.5% identity between the human and mouse Cosmc.
It is significant that Cosmc is located on the X chromosome, which may be relevant to understanding some human diseases that are associated with or result from acquired or inherited deficiencies in C1␤3Gal-T activity. For example, the Tn and sialyl Tn antigens are common markers in many types of tumors (7, 8) , indicating that alterations in expression of Cosmc and consequently the C1␤3Gal-T may be contributing factors for altered glycosylation by tumor cells. A loss of activity of C1␤3Gal-T caused by a mutation in Cosmc could result in increases in both Tn and sialyl Tn antigens. IgA nephropathy (Berger's disease) is characterized by a decreased galactose content of O-glycans of IgA1 (29) (30) (31) , which has five potential O-glycosylation sites in the hinge region. It has been proposed that the galactose deficiency in IgA1 of these patients results from a deficiency in C1␤3Gal-T activity (32) . Interestingly, IgA nephropathy exhibits a 2:1 male predominance (33), suggesting a possible X-linkage. Our results suggest that mutations in Cosmc, either genetically inherited or occurring randomly in a precursor stem cell, might be associated with decreased C1␤3Gal-T activity in select B-cell populations responsible for IgA1 production. Whether defects in Cosmc expression or in the direct expression of the C1␤3Gal-T are involved in other diseases associated with decreased C1␤3Gal-T activity and expression of Tn antigen, such as Tn syndrome and Henoch-Schönlein purpura, should also be investigated.
